Table 4.
Clinical trials of preemptive antiviral therapy for hepatitis B virus reactivation in patients with hepatitis B virus-related hepatocellular carcinoma
| Ref. | Study type | Cancer therapy | No of patients (Tx vs control) | Antiviral therapy | HBV reactivation (Tx vs control) | P value |
| Nagamatsu et al[10] | Retrospective | TAI | 17 (8 vs 9) | LAM | 0% vs 67% | 0.009 |
| Jang et al[17] | RCT | TACL | 73 (36 vs 37) | LAM | 2.8% vs 29.7% | 0.002 |
| Kim et al[6] | Retrospective | TACE + RT | 48 (16 vs 32) | LAM | 0% vs 21.8% | 0.048 |
| Huang et al[35] | Prospective | Hepatectomy | 164 (126 vs 38) | LAM, ETV, ADV, TBVD | 1.6% vs 21.1% | < 0.001 |
| Dan et al[38] | Retrospective | Hepatectomy, RFA | 218 (68 vs 150) | LAM, ETV, LAM + ADV | 2.9% vs 20.7%1 | 0.027 |
| 0% vs 7.6%2 | NS | |||||
| Huang et al[37] | RCT | Hepatectomy | 84 (40 vs 44) | TBVD | 2.5% vs 31.8% | 0.001 |
| Huang et al[16] | Retrospective | Hepatectomy | 1609 (150 vs 1459) | LAM, ETV, ADV | 4.7% vs 20.1% | < 0.001 |
1
Data following hepatectomy;
2
Data following RFA. HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; Tx: Treatment; RCT: Randomized controlled trial; TAI: Transarterial infusion chemotherapy; TACL: Transarterial chemo-lipiodolization; TACE: Transarterial chemo-embolization; RT: Radiotherapy; LAM: Lamivudine; ETV: Entecavir; ADV: Adefovir; TBVD: Telbivudine; NS: Not significant.